10-K Filing

Xenetic Biosciences, Inc. CIK: 1534525 FY 2022

Filing Information

Form Type	10-K
Accession Number	`0001683168-23-001674`
Period End Date	20221231
Filing Date	20230322
Fiscal Year	2022
Fiscal Period	FY
XBRL Instance	xenetic_i10k-123122_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 43 Income Statement 24 Cash Flow Statement 44 Stockholders Equity 17

Balance Sheet 43 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$18.24M	USD	Point-in-time
Cash	`Cash`	$13.10M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$556.09K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$479.40K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.65M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.72M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.09M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.07M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Total assets	`Assets`	$19.82M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.47M	shares	Point-in-time
Total assets	`Assets`	$14.72M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	15.19M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.44M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	15.17M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$287.36K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$362.47K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$785.80K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.06M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.07M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.07M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.42M	USD	Point-in-time
Commitments and contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 100,000,000 and 50,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 15,193,587 and 13,466,603 shares issued as of December 31, 2022 and December 31, 2021, respectively; 15,166,596 and 13,439,612 shares outstanding as of December 31, 2022 and December 31, 2021, respectively	`CommonStockValue`	$13.46K	USD	Point-in-time
Common stock, $0.001 par value; 100,000,000 and 50,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 15,193,587 and 13,466,603 shares issued as of December 31, 2022 and December 31, 2021, respectively; 15,166,596 and 13,439,612 shares outstanding as of December 31, 2022 and December 31, 2021, respectively	`CommonStockValue`	$15.19K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$205.95M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$207.76M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-189.10M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-182.55M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$13.65M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$18.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.22M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$14.72M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$19.82M	USD	Point-in-time

Income Statement 24 line items

Line Item	Tag	Value	Unit	Period
Royalty revenue	`RoyaltyIncomeNonoperating`	$1.16M	USD	Annual
Royalty revenue	`RoyaltyIncomeNonoperating`	$1.71M	USD	Annual
Total revenue	`Revenues`	$1.16M	USD	Annual
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	10.28M	shares	Annual
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	14.22M	shares	Annual
Total revenue	`Revenues`	$1.71M	USD	Annual
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	10.28M	shares	Annual
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	14.22M	shares	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.16M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.77M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.74M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.65M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$8.42M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$6.91M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-6.72M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-5.75M	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$1.12K	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-1.60K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$100.47K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$167.15K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$101.59K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$165.56K	USD	Annual
Net loss	`NetIncomeLoss`	$-6.55M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.65M	USD	Annual

Cash Flow Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-6.55M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.65M	USD	Annual
Acquired in-process research and development	`AcquiredInprocessResearchAndDevelopment`	-	USD	Annual
Acquired in-process research and development	`AcquiredInprocessResearchAndDevelopment`	$1.79M	USD	Annual
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$27.04K	USD	Annual
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$35.48K	USD	Annual
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$410.44K	USD	Annual
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$511.48K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInAccountsAndOtherReceivables`	$103.74K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-286.01K	USD	Annual
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$281.95K	USD	Annual
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-25.00K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-347.95K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$457.13K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.65M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.74M	USD	Annual
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	-	USD	Annual
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$500.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-500.00K	USD	Annual
Net proceeds from issuance of common stock and warrants	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Net proceeds from issuance of common stock and warrants	`ProceedsFromIssuanceOfCommonStock`	$11.45M	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$3.68K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.45M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$6.72M	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-5.15M	USD	Annual
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.10M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.10M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$1.29M	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	-	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$7.00	USD	Annual
Issuance of common stock in connection with warrant buyout	`IssuanceOfCommonStockInConnectionsWithWarrantBuyout`	-	USD	Annual
Issuance of common stock in connection with warrant buyout	`IssuanceOfCommonStockInConnectionsWithWarrantBuyout`	$41.07K	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$2.00	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$6.00	USD	Annual

Stockholders Equity 17 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$13.65M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Issuance of common stock in connection with purchase of in-process research and development	`IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment`	$1.29M	USD	Annual
Issuance of common stock and warrants, net of issuance costs	`StockIssuedDuringPeriodValueNewIssues`	$11.45M	USD	Annual
Exercise of pre-funded warrants	`ExerciseOfPrefundedWarrants`	$3.68K	USD	Annual
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$511.48K	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$410.44K	USD	Annual
Issuance of common stock to vendor	`StockIssuedDuringPeriodValueOther`	-	USD	Annual
Issuance of common stock in connection with warrant buyout	`IssuanceOfCommonStockInConnectionWithWarrantBuyout`	$41.07K	USD	Annual
Net loss	`NetIncomeLoss`	$-6.55M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.65M	USD	Annual
Ending balance, value	`StockholdersEquity`	$13.65M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.